Comparative Pharmacology
Head-to-head clinical analysis: OSMITROL 15 IN WATER IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMITROL 15 IN WATER IN PLASTIC CONTAINER versus OSMITROL 5 IN WATER.
OSMITROL 15% IN WATER IN PLASTIC CONTAINER vs OSMITROL 5% IN WATER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular compartment, thereby reducing cerebral edema and intraocular pressure; also promotes diuresis by increasing renal tubular fluid osmolality.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
50-100 g intravenously as a 5% solution over 30-60 minutes; may repeat every 6-8 hours as needed. Maximum dose: 200 g in 24 hours.
None Documented
None Documented
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Approximately 0.25-1.5 hours (15-90 minutes); prolonged in renal impairment or with mannitol accumulation (e.g., in anuria).
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Primarily renal (90-100% unchanged in urine); negligible biliary or fecal elimination.
Category C
Category C
Osmotic Diuretic
Osmotic Diuretic